DeepMatter (AIM: DMTR), the AIM-quoted company focusing on digitising chemistry, is pleased to announce that Mirko Walter has been appointed to the Board as Non-Executive Director with immediate effect.
Mirko is currently Vice President Sales of Springer Nature, the global academic publishing company, and has been with the business for six years, supporting the Company's growth strategy through sales excellence, partnerships and portfolio expansion. In addition to his achievements in implementing and executing on sales strategies, Mirko has 18 years' experience working with customers to optimise their Research & Development processes and investments. Prior to joining Springer Nature, he was Head of Business Development at digital healthcare provider DocMorris, whilst it was part of McKesson Corporation, a leading company in the healthcare sector.
Mirko succeeds Bettina Goerner, who has stepped down from her operational role at Springer Nature, and therefore will step down from the DeepMatter Board effective today. Bettina joined the DeepMatter Board in March 2019, as part of the acquisition of InfoChem GmbH ("InfoChem") from Springer Nature. The Board thanks Bettina for her contribution to DeepMatter and oversight of the successful integration of the InfoChem business into the Group and wishes her all the very best for the future.
Mark Warne, Chief Executive Officer of DeepMatter commented: "I am delighted to welcome Mirko to the Board. Mirko's passion for working with customers to create innovation based on trusted information and leading data products coupled with his wealth of experience in sales and the scientific sector will resonate with DeepMatter's long-term strategic goal to commercialise the digitisation of chemistry. We look forward to working with Mirko as we scale up the business and enter new territories. We are grateful for the contribution Bettina made in the two years since the InfoChem acquisition and wish her all the very best for the future."
Mirko Walter, aged 40, holds no other listed company directorships, nor has he held any directorships during the five years prior to his appointment. He holds no interest in the ordinary shares of the Company. There are no further disclosures to be made in accordance with Rule 17 and paragraph (g) of Schedule 2(g) of the AIM Rules for Companies.